Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120569 | 0.85 | MAPT (0.61) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL14354433 | 0.82 | MAPT (0.50) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL8000052 | 0.78 | MAPT (0.63) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL17591690 | 0.77 | CYP3A4 (0.53) | MAPTKMT2ACYP1A2LMNA | |
| SCHEMBL2781433 | 0.77 | MAPT (0.68) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL29159698 | 0.77 | MAPT (0.68) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL368343 | 0.77 | MAPT (1.00) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL4989125 | 0.77 | MAPT (0.61) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL18650576 | 0.77 | CES1 (0.53) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL11602590 | 0.76 | MAPT (0.65) | MAPTKMT2AKCNN4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015184317-A1 | PHARMACEUTICAL COMPOSITION WITH IONICALLY CROSSLINKED POLYMER ENCAPSULATION OF ACTIVE INGREDIENT | ALLEN ERIC (US) | 2015-12-03 | — | — | WO | claimed |
| US-20260027068-A1 | METHODS OF ADMINISTERING R-KETAMINE | PERCEPTION NEUROSCIENCE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-11426367-B2 | Methods of treating substance abuse | PERCEPTION NEUROSCIENCE, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2015184317-A1 | PHARMACEUTICAL COMPOSITION WITH IONICALLY CROSSLINKED POLYMER ENCAPSULATION OF ACTIVE INGREDIENT | ALLEN ERIC (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2014178065-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-11-06 | — | — | WO | disclosed |
| WO-2012155090-A2 | HIGH SENSITIVITY MASS SPECTROMETRY SYSTEMS | ILLINOIS STATE UNIVERSITY (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-1709029-A2 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005075455-A2 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426367-B2 | Methods of treating substance abuse | OPRK1, TACR2, SLC6A3 | MAPT 1363/4885KMT2A 640/4885KCNN4 1150/4885 |
| US-20260027068-A1 | METHODS OF ADMINISTERING R-KETAMINE | SNCA, OPRD1, OPRK1 | MAPT 18/4885KMT2A 1022/4885KCNN4 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.